Inactief instrument

Andere talen Protagenic Therapeutics, Inc. Other OTC

Aandelen

PTIX

US74365N1037

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Protagenic Therapeutics Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial	23/05
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial	01/05
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders	27/03
Protagenic Therapeutics, Inc.	21/03
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders	14/02
Protagenic Therapeutics Achieves First Clinical Safety Milestone with Its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders	13/02
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12
Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	12/12
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14-08-23
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	31-03-23
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31-03-23
PROTAGENIC THERAPEUTICS, INC.NEW : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-03-23
Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director	29-11-22
PROTAGENIC THERAPEUTICS, INC.NEW : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	29-11-22
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	14-11-22
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14-11-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Protagenic Therapeutics, Inc. Other OTC

Aandelen

PTIX

US74365N1037

Andere talen

Filters